Current approaches to identify AD affected individuals include in vivo measures of the pathological hallmarks of disease—amyloid, tau, and neurodegeneration—via CSF biomarkers for amyloid and tau5, positron emission tomography for amyloid and tau6, and structural and functional MRI of neurodegeneration. This evidence concerns the gene MAPT and Alzheimer disease.